Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Juvenile Rheumatoid Arthritis AND Arthritis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    66 result(s) found for: Juvenile Rheumatoid Arthritis AND Arthritis. Displaying page 3 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2012-000444-10 Sponsor Protocol Number: WA28029 Start Date*: 2012-11-09
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A PHASE IV STUDY TO EVALUATE DECREASED DOSE FREQUENCY IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WHO EXPERIENCE LABORATORY ABNORMALITIES DURING TREATMENT WITH TOCILIZUMAB
    Medical condition: Systemic juvenile idiopathic arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) NO (Completed) DE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004887-39 Sponsor Protocol Number: SB5-G21-RA Start Date*: 2015-08-08
    Sponsor Name:Samsung Bioepis Co., Ltd
    Full Title: An Open-labelled, Single-arm, Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects with Rheumatoid Arthritis
    Medical condition: Subjects with Rheumatoid Arthritis. The intended use of SB5 is rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA), adult Crohn's disease (CD), paediatric CD, ankylosing sp...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005479-82 Sponsor Protocol Number: CACZ885G2301 Start Date*: 2009-06-12
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio doble ciego, randomizado, controlado con placebo, con diseño de retirada en la prevención de brotes con canakinumab (ACZ885) en pacientes con artritis idiopática juvenil sistémica y manifes...
    Medical condition: Artritis idiopática juvenil sistémica y manifestaciones sistémicas activas.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) NO (Ongoing) FR (Completed) HU (Completed) BE (Completed) DE (Completed) SE (Completed) IT (Completed) GB (Completed) DK (Prematurely Ended) AT (Completed) GR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004518-24 Sponsor Protocol Number: I4V-MC-JAHV Start Date*: 2019-04-23
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Juvenile Idiopathic Arthritis (JIA)
    Medical condition: Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) DE (Completed) AT (Completed) ES (Ongoing) PL (Completed) FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005013-13 Sponsor Protocol Number: SB5-G31-RA Start Date*: 2014-04-03
    Sponsor Name:Samsung Bioepis Co., Ltd.
    Full Title: A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity of SB5 Compared to Humira® in Subjects wit...
    Medical condition: Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy. The intended use of SB5 is rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA), adult Cr...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-001438-46 Sponsor Protocol Number: A3921104 Start Date*: 2018-03-27
    Sponsor Name:Pfizer Inc.
    Full Title: EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS
    Medical condition: JUVENILE IDIOPATHIC ARTHRITIS (JIA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004915-22 Sponsor Protocol Number: A3921145 Start Date*: 2012-08-03
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017
    Full Title: A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)
    Medical condition: JUVENILE IDIOPATHIC ARTHRITIS (JIA)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004859 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) PL (Trial now transitioned) DE (Completed) SK (Completed) IT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Prematurely Ended) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-018027-33 Sponsor Protocol Number: RA0043 Start Date*: 2024-08-30
    Sponsor Name:UCB BIOSCIENCES GmbH
    Full Title: A multicenter, open-label study to assess the pharmacokinetics, safety and efficacy of certolizumab pegol in children and adolescents with moderately to severely active polyarticular-course juvenil...
    Medical condition: Juvenile Idiopathic Arthritis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002466-22 Sponsor Protocol Number: 990758 Start Date*: 2015-12-23
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Open­label Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-...
    Medical condition: Juvenile Rheumatoid Arthritis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003358-27 Sponsor Protocol Number: HUM06-037 Start Date*: 2008-05-02
    Sponsor Name:Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin
    Full Title: Phase III, multi-center, randomized, double blind, placebo-controlled study for treatment of juvenile ankylosing spondylitis with Adalimumab
    Medical condition: Juvenile ankylosing spondylitis
    Disease: Version SOC Term Classification Code Term Level
    10 10002556 LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001661-40 Sponsor Protocol Number: DE038 Start Date*: 2012-02-07
    Sponsor Name:Abbott Laboratories
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Juvenile Rheuma...
    Medical condition: Polyarticular Juvenile Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10036039 Polyarticular juvenile rheumatoid arthritis, chronic or unspecified LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-003737-26 Sponsor Protocol Number: A3191342 Start Date*: 2015-04-07
    Sponsor Name:Pfizer Inc
    Full Title: A Phase 4, 6-week, randomized double-blind, multicenter, active-controlled trial to evaluate the effects of Celecoxib (Celebrex®) or Naproxen on blood pressure in paediatric subjects with juvenile ...
    Medical condition: Juvenile idiopathic arthritis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004103-73 Sponsor Protocol Number: 0881A1-207 Start Date*: 2015-03-12
    Sponsor Name:Wyeth Kabushiki Kaisha (Wyeth K.K.)
    Full Title: A long-term, open-label study of TNR-001 in Japanese Juvenile Idiopathic Arthritis Subjects.
    Medical condition: Juvenile idiopathic arthritis (JIA)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004284-30 Sponsor Protocol Number: CAN_1_2018 Start Date*: 2020-02-13
    Sponsor Name:Asklepios Klink Sankt Augustin
    Full Title: Effectiveness of Canakinumab for first line steroid free treatment in systemic onset juvenile idiopathic arthritis / juvenile Still’s disease
    Medical condition: systemic juvenile idiopathic arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10079454 Systemic juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001171-37 Sponsor Protocol Number: 20021626 Start Date*: 2012-03-07
    Sponsor Name:Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320
    Full Title: A Phase IV Registry of Etanercept in Children With Juvenile Rheumatoid Arthritis
    Medical condition: Juvenile idiopathic arthritis (JIA)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005026-30 Sponsor Protocol Number: SB4-G31-RA Start Date*: 2013-08-15
    Sponsor Name:Samsung Bioepis Co., Ltd.
    Full Title: A Randomised, Double-Blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel® in Subjects with Moderate to ...
    Medical condition: Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy. The intended use of SB4 is Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (P...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-015019-42 Sponsor Protocol Number: CNTO148JIA3001 Start Date*: 2011-05-10
    Sponsor Name:Janssen Biologics B.V.
    Full Title: A Multicenter, Double Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects with Active Polyarticular Course Juvenile Idiopathic Arthritis ...
    Medical condition: Juvenile Idiopathic Arthritis (JIA)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) BE (Completed) LT (Prematurely Ended) FI (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-001027-20 Sponsor Protocol Number: CACZ885GDE01T Start Date*: 2012-04-03
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension.
    Medical condition: adult onset Still's disease (AOSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042061 Still's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004495-60 Sponsor Protocol Number: I4V-MC-JAHU Start Date*: 2019-09-24
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less than 18 Years Old with Systemic Juvenile Idiopathic Arthrit...
    Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10079454 Systemic juvenile idiopathic arthritis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) DK (Prematurely Ended) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002018-29 Sponsor Protocol Number: A3921165 Start Date*: 2020-12-09
    Sponsor Name:Pfizer Inc.
    Full Title: EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS
    Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10079454 Systemic juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed) DE (Completed) BE (Completed) IT (Completed) NL (Prematurely Ended) SE (Prematurely Ended) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 07:36:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA